AUTL Key Statistics, Chart & Performance
The current stock price of AUTL is 1.87 USD. In the past month the price increased by 32.62%. In the past year, price decreased by -30.22%.
AUTL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About AUTL
Company Profile
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Company Info
AUTOLUS THERAPEUTICS PLC
The Mediaworks, 191 Wood Lane
London W12 7RZ GB
CEO: Christian Itin
Employees: 647
Phone: 442038296230
AUTOLUS THERAPEUTICS PLC / AUTL FAQ
What does AUTL do?
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Can you provide the latest stock price for AUTOLUS THERAPEUTICS PLC?
The current stock price of AUTL is 1.87 USD. The price increased by 11.98% in the last trading session.
What is the dividend status of AUTOLUS THERAPEUTICS PLC?
AUTL does not pay a dividend.
What is the ChartMill rating of AUTOLUS THERAPEUTICS PLC stock?
AUTL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for AUTOLUS THERAPEUTICS PLC?
AUTOLUS THERAPEUTICS PLC (AUTL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for AUTOLUS THERAPEUTICS PLC?
AUTOLUS THERAPEUTICS PLC (AUTL) has a market capitalization of 497.69M USD. This makes AUTL a Small Cap stock.
What is the ownership structure of AUTOLUS THERAPEUTICS PLC (AUTL)?
You can find the ownership structure of AUTOLUS THERAPEUTICS PLC (AUTL) on the Ownership tab.
AUTL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AUTL. When comparing the yearly performance of all stocks, AUTL is a bad performer in the overall market: 72.92% of all stocks are doing better.
AUTL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AUTL. While AUTL seems to be doing ok healthwise, there are quite some concerns on its profitability.
AUTL Financial Highlights
Over the last trailing twelve months AUTL reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 31.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.96% | ||
| ROE | -84.69% | ||
| Debt/Equity | 0.95 |
AUTL Forecast & Estimates
17 analysts have analysed AUTL and the average price target is 9.35 USD. This implies a price increase of 400.18% is expected in the next year compared to the current price of 1.87.
For the next year, analysts expect an EPS growth of -13.2% and a revenue growth 503.05% for AUTL